-
Innovation Ranking
NewInnovation Ranking – Betta Pharmaceuticals Co Ltd
Betta Pharmaceuticals Co Ltd (Betta Pharmaceuticals), discovers, develops, and supply drugs for the treatment of cancer and diabetes. Its products include icotinib hydrochloride, an orally administered small-molecule, reversible tyrosine kinase inhibitor for treating locally advanced or metastatic non-small cell lung cancer; and ensartinib hydrochloride capsules to treat ALK-mutated advanced non-small cell lung cancer. The company has also developed beantine, a macromolecular biological product for treatment of recurrent non-small lung cancer. Betta Pharmaceuticals is developing its pipeline with small and macromolecules...
-
Company Insights
Innovation and Patenting activity of Betta Pharmaceuticals Co Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Betta Pharmaceuticals Co Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vorolanib in Thymic Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vorolanib in Thymic Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vorolanib in Thymic Carcinoma Drug Details: Vorolanib (Fumena) is an indoline derivative....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vorolanib in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vorolanib in Metastatic Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vorolanib in Metastatic Melanoma Drug Details: Vorolanib (Fumena) is an indoline derivative....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABBV-101 in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABBV-101 in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ABBV-101 in Extranodal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Efgartigimod Alfa in Primary Sjogren’s Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Efgartigimod Alfa in Primary Sjogren's Syndrome report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Efgartigimod Alfa in Primary Sjogren's Syndrome Drug Details: Efgartigimod...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vorolanib in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vorolanib in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vorolanib in Non-Small Cell Lung Cancer Drug Details: Vorolanib (Fumena)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ensartinib Hydrochloride in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ensartinib Hydrochloride in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ensartinib Hydrochloride in Non-Small Cell Lung Cancer Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Niraparib in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Niraparib in Small-Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Niraparib in Small-Cell Lung Cancer Drug Details: Niraparib (MK-4827, Zejula)...
-
Product Insights
Neurofibromatoses Type II – Drugs In Development, 2023
Global Markets Direct’s, ‘Neurofibromatoses Type II - Drugs In Development, 2023’, provides an overview of the Neurofibromatoses Type II pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neurofibromatoses Type II, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...